SEARCH

SEARCH BY CITATION

References

  • 1
    National Osteoporosis Guideline Group. Guideline for the Diagnosis and Management of Osteoporosis. Sheffield: NOGG; 2010 [http://www.shef.ac.uk/NOGG/NOGG_Pocket_Guide_for_Healthcare_Professionals.pdf].
  • 2
    Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:46575.
  • 3
    National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington DC: National Osteoporosis Foundation; 2010 [http://www.nof.org/sites/default/files/pdfs/NOF_ClinicianGuide2009_v7.pdf].
  • 4
    World Health Organization. WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level. Summary Meeting Report: Brussels, Belgium, 5-7 May 2004. Geneva: WHO; 2007 [www.who.int/chp/topics/Osteoporosis.pdf].
  • 5
    International Osteoporosis Foundation [www.iofbonehealth.org/].
  • 6
    Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 2010;16(Suppl 3):137.
  • 7
    North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:2554.
  • 8
    Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Oglesby A. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 2002;17:123744.
  • 9
    International Society for Clinical Densitometry. 2007 ISCD Official Positions. Middleton, CT: ISCD; 2007 [www.iscd.org/visitors/positions/OfficialPositionsText.cfm].
  • 10
    U.S Preventive Services Task Force. Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med 2011;154:35664.
  • 11
    Marcocci C, Cetani F. Primary hyperparathyroidism. N Engl J Med 2011;365:238997.
  • 12
    Campbell AJ, Borrie MJ, Spears GF. Risk factors for falls in a community-based prospective study of people 70 years and older. J Gerontol 1989;44:M1127.
  • 13
    Gates S, Fisher JD, Cooke MW, Carter YH, Lamb SE. Multifactorial assessment and targeted intervention for preventing falls and injuries among older people in community and emergency care settings: systematic review and meta-analysis. BMJ 2008;336:1303.
  • 14
    Bonaiuti D, Shea B, Iovine R, Negrini S, Robinson V, Kemper HC, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2002;(3):CD000333.
  • 15
    Feskanich D, Willett W, Colditz G. Walking and leisure-time activity and risk of hip fracture in postmenopausal women. JAMA 2002;288:2300.
  • 16
    Hopper JL, Seeman E. The bone density of female twins discordant for tobacco use. N Engl J Med 1994;330:387.
  • 17
    Berg KM, Kunins HV, Jackson JL, Nahvi S, Chaudhry A, Harris KA Jr, et al. Association between alcohol consumption and both osteoporotic fracture and bone density. Am J Med 2008;121:40618.
  • 18
    Parker MJ, Gillespie WJ, Gillespie LD. Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review. BMJ 2006;332:57174.
  • 19
    Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010;341:c3691.
  • 20
    Khosla S, Melton J. Osteopenia. N Engl J Med 2007;356:2293300.
  • 21
    National Institute for Health and Clinical Excellence. Appraisal Consultation Document. Alendronate, Etidronate, Risedronate, Raloxifene and Strontium Ranelate for the Primary Prevention of Osteoporotic Fragility Fractures in Postmenopausal Women. London: NICE; 2007.
  • 22
    National Institute for Health and Clinical Excellence. Final Appraisal Determination. Alendronate, Etidronate, Risedronate, Raloxifene, Strontium Ranelate and Teriparatide for the Secondary Prevention of Osteoporotic Fragility Fractures in Postmenopausal Women. London: NICE; 2007.
  • 23
    National Institute for Health and Clinical Excellence. Final Appraisal Determination. Alendronate, Etidronate, Risedronate, Raloxifene and Strontium Ranelate for the Primary Prevention of Osteoporotic Fragility Fractures in Postmenopausal Women. London: NICE; 2007.
  • 24
    Kanis JA, Adams J, Borgstrom F, Cooper C, Jönsson B, Preedy D, et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone 2008;42:415.
  • 25
    Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9:1160.
  • 26
    Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:292738.
  • 27
    Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:226794.
  • 28
    Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:147991.
  • 29
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:32133.
  • 30
    The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomised Controlled Trial. JAMA 2004;291:170112.
  • 31
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:63745.